Novo Nordisk A/S: Novo Nordisk increased operating profit by 32% in 2012
BAGSVAERD, DENMARK -- (Marketwire) -- 01/31/13 -- Sales growth of
18% driven by Victoza(R), NovoRapid(R) and Levemir(R) Sales increased
by 18% to 78.0 billion in Danish kroner and by 12% in local
* Sales of modern insulins increased by 21% (15% in local
* Sales of Victoza(R) increased by 58% (50% in local currencies).
* Sales in North America increased by 29% (19% in local
* Sales in International Operations increased by 18% (16% in local
Reported operating profit increased by 32% to DKK 29.5 billion
including a 1.7
percentage points improvement in the gross margin.
Measured in local currencies,
operating profit increased by 20%.
Company announcement No 8 / 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
CONTACTS FOR FURTHER INFORMATION
+45 4442 3573
Ken Inchausti (US)
+1 609 514 8316
Kasper Roseeuw Poulsen
+45 4442 4303
Frank Daniel Mersebach
+45 4442 0604
Lars Borup Jacobsen
+45 3075 3479
Jannick Lindegaard (US)
+1 609 786 4575
Press spacebar to pause and continue. Press esc to stop.